Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein

Name: Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein
Brand: Puweituo Bio
SKU: KRASG12R-HP002

Catalog numberKRASG12R-HP002

HumanHEK293Molecule · MHCMolecular weight · 258 kDa

Product introduction

Recombinant Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGARGVGK peptide (accession: AAV53343.1(HLA-A*11:01) & P61769(B2M) &VVVGARGVGK).

Product details

Molecular aliases: MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
Protein length: Gly25-Thr305
Expression system: HEK293
Molecular weight: The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reduced (N) condition based on Bis-Tris PAGE result.
Purity: > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin: Less than 1 EU per μg by the LAL method.
Formulation: Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State: Lyophilized
Storage: -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution: Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data display

Bis-Tris PAGE Data — Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.

SEC-HPLC Data — The purity of Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer is greater than 95% as determined by SEC-HPLC.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

References

1.(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

加载中…

Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein

Catalog numberKRASG12R-HP002

HumanHEK293Molecule · MHCMolecular weight · 258 kDa

Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein

Product introduction

Product details

Data display

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

Background

References

Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein

Product introduction

Product details

Data display

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

Background

References